Kalevi Kairemo - Concepedia

Author

Kalevi Kairemo

Also Known As

K J Kairemo, K Kairemo, K. J. A. KAIREMO, K. J. A. Kairemo, K. J. KAIREMO, K. J. Kairemo, K. J.A. KAIREMO, K. J.A. Kairemo, K. KAIREMO, K. Kairemo

310

Publications

Citations

H-Index

Concepts

All Affiliations

Helsinki University Hospital Docrates Cancer Center University of Helsinki The University of Texas MD Anderson Cancer Center Oncos Therapeutics (Finland)

About

Kalevi Kairemo is an author at Helsinki University Hospital specializing in medicine, radiation oncology, and radiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	25	944
2	Health Sciences	11	14	361
3	Engineering	7	7	351
4	Public Health	1	1	18
5	Anesthesia	1	1	37

Kalevi Kairemo

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers Tuuli Ranki, Sari Pesonen, Akseli Hemminki, Journal for ImmunoTherapy of Cancer	2016	198
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus Anna Kanerva, Petri Nokisalmi, Iulia Diaconu, Clinical Cancer Research	2013	175
Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients Sari Pesonen, Iulia Diaconu, Lotta Kangasniemi, Cancer Research ImmunologyImmunoeditingImmunodominanceCd4 T Cell ResponsesImmunotherapeutics	2012	137
Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Ester Fonsatti, Antti Jekunen, Kalevi Kairemo, PubMed Breast OncologyEngineeringEndothelial CellsSolid TumorsOncologic Imaging	2000	135
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P. Baum, European Journal of Nuclear Medicine and Molecular Imaging	2020	124
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy Otto Hemminki, Suvi Parviainen, Juuso Juhila, Oncotarget	2015	85
Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer Otto Hemminki, Iulia Diaconu, Vincenzo Cerullo, Molecular Therapy	2012	85
Nanoparticles in Cancer Ernest K. J. Pauwels, Kalevi Kairemo, Paola Anna Erba, Current Radiopharmaceuticals NanoparticlesNanotherapeuticsEngineeringCancer ManagementCancer Diagnostics Nanoparticles	2008	77
Elimination of Stabilised Hyaluronan from the Knee Joint in Healthy Men Ulla Lindqvist, Vladimir Tolmachev, Kalevi Kairemo, Clinical Pharmacokinetics Knee JointBiomechanicsOsteoarthritisSurgeryJoint Replacement	2002	76
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy Ilkka Liikanen, Anniina Koski, Maiju Merisalo-Soikkeli, OncoImmunology	2015	58

Page 1